Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Costco will not sell the medical abortion pill mifepristone across any of its U.S. pharmacy locations.
read more
Brinsupri tablets are the the first treatment for non-cystic fibrosis bronchiectasis.
read more
Hernexeos tablets are the first orally-administered targeted therapy for HER2 (ERBB2)-mutant advanced NSCLC.
read more
The completed deal comes with the acquisition of an oral small molecule in phase 2 trials for Alzheimer’s disease.
read more
The acquisition of Regis will enable Esteve's expansion into the U.S. for whole drug development of small-molecule APIs.
read more
Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults.
read more
The once-daily pill, orforglipron, has demonstrated similar safety and tolerability to injectable GLP-1 therapies.
read more
The company's investigational selective NaV1.8 pain signal inhibitor, VX-993, failed to best placebo in a phase 2 trial.
read more
New FDA labeling requirements will emphasize the risks of using pain meds for extended periods.
read more
Letters were sent to 17 pharma companies demanding they bring down prices of prescription drugs in the U.S. to match the lowest price offered in other developed nations.
read more
Madrigal has finalized a global license deal that could exceed $2B for a preclinical drug to treat MASH.
read more
Sephience is approved for the treatment of children and adults living with phenylketonuria, a rare metabolic disease that affects the brain.
read more
The Johor plant is Colorcon’s 7th major film coating plant and its 16th manufacturing facility worldwide.
read more
Novartis will pay up to $1B for the rights to commercialize resulting oral covalent inhibitors in multiple inflammatory diseases.
read more
The review period for the once-daily, non-hormonal treatment, elinzanetant, will be extended for up to 90 days.
read more